Your Health, We Care
Release date: 2024-08-28 16:50:08 Recommended: 181
Stiripentol was approved by the FDA in 2018 for significantly improving seizure frequency and improving the quality of life of infants and young children suffering from Dravet syndrome through its unique mechanism of action.
Before purchasing and using a drug, knowing who the drug is suitable for can help the patient make the right choice of medication.
Stiripentol is mainly used for the treatment of seizures associated with Dravet syndrome (DS) and is indicated for patients who are taking clobazam and are over 6 months of age and weigh 7 kg or more. Currently, there are no clinical data to prove that Stiripentol can be used alone in the treatment of Dravet syndrome.
With the clinical application of drugs, more and more patients pay attention to the therapeutic effect of drugs.
According to clinical trial data, the therapeutic effects of Stiripentol can be summarized as:
In clinical studies, Stiripentol has shown significant efficacy. In the first experiment, most of the patients in the Stiripentol treatment group achieved a significant reduction in seizure frequency, and the efficacy was significantly better than that of the Placebo group. In the second experiment, where the study was terminated early and the sample size was small, Stiripentol still showed excellent efficacy, with significantly more patients in the Placebo group achieving a reduction in seizure frequency.
These results suggest that Stiripentol is significantly effective in reducing seizure frequency. Patients should also pay attention to information on the dosage and dosage of medicines.
How to use Stiripentol is information that patients pay close attention to, according to the drug label:
The recommended dose of Stiripentol is 50 mg/kg daily in 2 or 3 divided doses, depending on the patient's age and weight. If the exact dose cannot be calculated, the desired dose can be achieved by rounding up to a range between 50 mg and 150 mg and combining different strengths of the drug. The maximum daily dose is 3,000 mg.
For patients with Dravet syndrome older than 6 months and weighing 7 kg or more, a total daily dose of 50 mg is recommended in two divided doses (25 mg each), with a maximum dose of 300 mg. Regardless of the specific value of the weight between 7 and 10 kg, the medication should not be taken more than twice a day.
The dosage in the instructions is only the general dosage of the drug, and the specific medication should be taken according to the doctor's instructions.
[Warm tips] As a targeted drug, the mechanism of action of Stiripentol is different from that of traditional drugs, and patients need to pay special attention to their own drug reactions during the medication process, and seek medical attention in time if they have questions or discomfort.
